Replies to post #18530 on Relief Therapeutics Holding AG (RLFTF)

[randychub]

You mean like this partnership - AbbVie will pay I-Mab USD 180 million in an upfront payment to exclusively license lemzoparlimab, along with USD 20 million in a milestone payment based on the phase 1 results, for a total of USD 200 million.

[pnnymn]

They have already plans for production and distribution and all this w/o FDA approval. They will need a partner to help with these costs. GEEZ